Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety of plerixafor and other outcomes that are purely exploratory
in nature. One other pre-specified outcome is to evaluate an interval of 10-11 hours between
dosing with plerixafor and the beginning of apheresis to determine if there will be at least
a 2-fold increase in circulating CD34+ cells. Data from this protocol will assist in the
determination of the dosing schedule for future studies.